MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced the start of the Engager™ European Pivotal Trial to pursue CE (Conformité Européenne) Mark for the Engager Transcatheter Aortic Valve Implantation System in patients suffering from severe aortic stenosis. The 150-person trial will be conducted at 11 centers in Germany, Israel, France, Belgium and Switzerland, and will evaluate the safety and clinical performance of the new valve and delivery system.
